

**IN THE MATTER OF  
CITY ACCESS PHARMACY  
PERMIT NO. P08345**

\*  
\*  
\*  
\*

**BEFORE THE MARYLAND  
STATE BOARD OF  
PHARMACY  
Case No. 23-340**

\* \* \* \* \*

**SUPPLEMENTAL ORDER**

WHEREAS, the Maryland Board of Pharmacy (the “Board”) entered into a Pre-Charge Consent Order with City Access Pharmacy (the “Pharmacy”) on May 15, 2023;

WHEREAS, the Pre-Charge Consent Order required, among other things, that the Pharmacy cease all sterile compounding operations unless and until: (a) Pharmacist A, the owner and manager, satisfactorily completed USP 797 training by a Board-approved training organization and submitted written proof of completion to the Board; and (b) the Pharmacy submitted to a Board inspection to ensure compliance with USP 797 requirements prior to re-commencing sterile compounding operations;

WHEREAS, on June 12, 2023, Pharmacist A submitted documentation evidencing his successful completion of USP 797 training by a Board-approved training organization;

WHEREAS, on July 20, 2023, the Pharmacy underwent annual and sterile compounding inspections by the Board which indicated that the Pharmacy’s USP and other facility deficiencies had been addressed;

WHEREAS, the Pharmacy has complied with all other conditions set forth in the Pre-Charge Consent Order;

WHEREAS, the Board reviewed the above submission and inspections, and subsequently voted to approve the Pharmacy’s request to re-commence its sterile compounding operations

with terms as set forth below.

**ORDER**

Based on an affirmative vote of the Board, it is this 10<sup>th</sup> day of October, 2023, hereby,

**ORDERED** that the Pharmacy may commence sterile compounding operations upon the date of this Supplemental Order; and be it further,

**ORDERED** that the Pharmacy's operations, and in particular the Pharmacy's sterile and non-sterile compounding practices, are subject to inspection by the Board; and be it further,

**ORDERED** that the Board may initiate disciplinary or emergency action against the Pharmacy should further inspections or any environmental or quality assurance test results indicate deficiencies which may pose a risk to public health and safety; and be it further,

**ORDERED** that this document constitutes a final order of the Maryland State Board of Pharmacy and is therefore a public document for purposes of public disclosure, pursuant to the Public Information Act, General Provisions Art. § 4-333 and COMAR 10.34.01, and shall be posted and reported in accordance with State and federal laws.

10-10-23  
Date

Deena Speights-Napata  
Deena Speights-Napata, M.A.  
Executive Director